Back to News
Market Impact: 0.35
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Source: 247wallst.com
Healthcare & BiotechAnalyst InsightsCompany Fundamentals
Moderna shares rose 4% to $217 this morning despite a valuation downgrade, as investors weighed strong cancer-vaccine data against expectations already reflected in the share price. The article gives no details on the data or the downgrade.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
MRNA0.35
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target